Submission of Unaudited Financial Results for the Quarter and Half Year Ended 30th September 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.4 pts more than Nifty Microcap 250 and 7.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Phaarmasia Ltd reported a sharp turnaround for Q2 FY26 (ended Sep 30, 2025), with revenue from operations jumping to Rs. 1,655.09 lakhs from Rs. 687.36 lakhs in Q2 FY25 — a growth of about 141% year-on-year. For the half year, revenue rose 65% to Rs. 2,342.45 lakhs from Rs. 1,421.72 lakhs a year ago. Net profit for the quarter surged to Rs. 173.59 lakhs (vs Rs. 27.02 lakhs in Q2 FY25), and the company swung to a half-yearly profit of Rs. 200.60 lakhs compared with a loss of Rs. 36.51 lakhs in H1 FY25. Basic EPS for the half year stood at Rs. 2.94 against a loss of Rs. 0.53 in the same period last year. Total assets more than doubled to Rs. 4,426 lakhs from Rs. 2,156 lakhs as at March 2025, while operating cash flow remained modestly positive at Rs. 15.12 lakhs. Statutory auditors Sathuluri & Co issued an unqualified limited review report.
Strong revenue growth and a clear swing back to profitability should be viewed positively by shareholders, suggesting improving demand and better cost absorption. Investors should watch whether this momentum sustains beyond a single quarter and if margins continue to expand.